Novartis' (NOVN SW/NVS) Ianalumab receives FDA breakthrough therapy designation for Sjögren’s disease and plans global submission in early 2026

Novartis has received FDA breakthrough therapy designation for Ianalumab to treat Sjögren’s disease, which indicates a significant validation of its potential and may accelerate its path to market.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

US reportedly explores plan to swap heavy Venezuelan oil for US medium crude to fill SPR, according to reports

US Treasury reportedly considering quarterly 7-year note auctions with reopening's

Novartis' (NOVN SW/NVS) Ianalumab receives FDA breakthrough therapy designation for Sjögren’s disease and plans global submission in early 2026

Venezuelan opposition leader Machado will not reveal details of conversation with Trump and did insist on returning to Venezuela as soon as possible

US President Trump says he had a great meeting on Healthcare this morning, government money must be paid, not to the insurance companies, but directly to the people; Healthcare will be provided at a substantially reduced cost

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

The plan for a global submission by early 2026 suggests confidence in regulatory support, potentially enhancing Novartis's competitive position in the pharmaceuticals sector. This development could positively affect investor sentiment and expectations regarding pipeline growth and future revenues.

Related headlines

The whole workspace, free to try.

Try it free